Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 1, 2006, Pages 113-120

  Schwarz, Patrick ^a   Dromer, Françoise ^a   Lortholary, Olivier ^a,b   Dannaoui, Eric ^a,b  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; FLUCYTOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BRAIN; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; INOCULATION; LUNG; MALE; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL TIME;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; BRAIN; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FLUCYTOSINE; LUNG;

EID: 29944435853     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.1.113-120.2006     Document Type: Article

References (33)

1. Andes, D., and M. van Ogtrop. 2000. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob. Agents Chemother. 44:938-942.
2. Bennett, J. E., W. E. Dismukes, R. J. Duma, G. Medoff, M. A. Sande, H. Gallis, J. Leonard, B. T. Fields, M. Bradshaw, H. Haywood, Z. A. McGee, T. R. Cate, C. G. Cobbs, J. F. Warner, and D. W. Alling. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med. 301:126-131.
3. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, R. J. Hamill, P. G. Pappas, A. L. Reingold, D. Rimland, and D. W. Warnock. 2001. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob. Agents Chemother. 45:3065-3069.
4. Brouwer, A. E., A. Rajanuwong, W. Chierakul, G. E. Griffin, R. A. Larsen, N. J. White, and T. S. Harrison. 2004. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363:1764-1767.
5. Chrétien, F., O. Lortholary, I. Kansau, S. Neuville, F. Gray, and F. Dromer. 2002. ZPathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J. Infect. Dis. 186:522-530.
6. Cuenca-Estrella, M., T. M. Diaz-Guerra, E. Mellado, and J. L. Rodriguez-Tudela. 2001. Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur. J. Clin. Microbiol. Infect. Dis. 20:276-279.
7. Diamond, D. M., M. Bauer, B. E. Daniel, M. A. Leal, D. Johnson, B. K. Williams, A. M. Thomas, J. C. Ding, L. Najvar, J. R. Graybill, and R. A. Larsen. 1998. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob. Agents Chemother. 42:528-533.
8. Ding, J. C., M. Bauer, D. M. Diamond, M. A. Leal, D. Johnson, B. K. Williams, A. M. Thomas, L. Najvar, J. R. Graybill, and R. A. Larsen. 1997. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41:1589-1593.
9. Dromer, F., S. Mathoulin-Pelissier, A. Fontanet, O. Ronin, B. Dupont, and O. Lortholary. 2004. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 18:555-562.
10. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
11. Hamilton, J. D., and D. M. Elliott. 1975. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J. Infect. Dis. 131:129-137.
12. Hospenthal, D. R., and J. E. Bennett. 1998. Flucytosine monotherapy for cryptococcosis. Clin. Infect. Dis. 27:260-264.
13. Karyotakis, N. C., and E. J. Anaissie. 1996. Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis. Antimicrob. Agents Chemother. 40:2907-2908.
14. Kwon-Chung, K. J., and J. E. Bennett. 1992. Medical mycology. Lea & Febiger, Philadelphia, Pa.
15. Larabi, M., N. Pages, F. Pons, M. Appel, A. Gulik, J. Schlatter, S. Bouvet, and G. Barratt. 2004. Study of the toxicity of a new lipid complex formulation of amphotericin B. J. Antimicrob. Chemother. 53:81-88.
16. Larsen, R. A., M. Bauer, A. M. Thomas, and J. R. Graybill. 2004. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob. Agents Chemother. 48:985-991.
17. Larsen, R. A., M. Bauer, J. M. Weiner, D. M. Diamond, M. E. Leal, J. C. Ding, M. G. Rinaldi, and J. R. Graybill. 1996. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob. Agents Chemother. 40:2178-2182.
18. Lortholary, O., L. Improvisi, M. Nicolas, F. Provost, B. Dupont, and F. Dromer. 1999. Fungemia during murine cryptococcosis sheds some light on pathophysiology. Med. Mycol. 37:169-174.
19. Lortholary, O., M. Nicolas, S. Soreda, L. Improvisi, O. Ronin, O. Petitjean, B. Dupont, M. Tod, and F. Dromer. 1999. Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. J. Antimicrob. Chemother. 43:817-824.
20. Medoff, G., M. Comfort, and G. S. Kobayashi. 1971. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc. Soc. Exp. Biol. Med. 138:571-574.
21. Mirza, S. A., M. Phelan, D. Rimland, E. Graviss, R. Hamill, M. E. Brandt, T. Gardner, M. Sattah, G. P. de Leon, W. Baughman, and R. A. Hajjeh. 2003. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin. Infect. Dis. 36:789-794.
22. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
23. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. M-27A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Nguyen, M. H., L. K. Najvar, C. Y. Yu, and J. R. Graybill. 1997. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41:1120-1123.
25. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, G. V. Doern, and D. J. Diekema. 2005. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43:2163-2167.
26. Polak, A., H. J. Scholer, and M. Wall. 1982. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy 28:461-479.
27. Saag, M. S., G. A. Cloud, J. R. Graybill, J. D. Sobel, C. U. Tuazon, P. C. Johnson, W. J. Fessel, B. L. Moskovitz, B. Wiesinger, D. Cosmatos, L. Riser, C. Thomas, R. Hafner, W. E. Dismukes, et al. 1999. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 28:291-296.
28. Saag, M. S., R. J. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, W. G. Powderly, J. D. Sobel, and W. E. Dismukes. 2000. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 30:710-718.
29. Schwarz, P., F. Dromer, O. Lortholary, and E. Dannaoui. 2003. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob. Agents Chemother. 47:3361-3364.
30. Shadomy, S., G. Wagner, E. Espinel-Ingroff, and B. A. Davis. 1975. In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob. Agents Chemother. 8:117-121.
31. Te Dorsthorst, D. T., P. E. Verweij, J. F. Meis, and J. W. Mouton. 2005. Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 49:4220-4226.
32. van der Horst, C. M., M. S. Saag, G. A. Cloud, R. J. Hamill, J. R. Graybill, J. D. Sobel, P. C. Johnson, C. U. Tuazon, T. Kerkering, B. L. Moskovitz, W. G. Powderly, W. E. Dismukes, et al. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337:15-21.
33. Vermes, A., H. J. Guchelaar, and J. Dankert. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46:171-179.